NuCana (NCNA) Change in Intangibles (2017 - 2025)
NuCana (NCNA) reported Change in Intangibles of -$66508.3 for Q4 2025, down 3.64% on a YoY basis from -$69017.6 in Q4 2024, and down 4.87% sequentially from -$63420.0 in Q3 2025.
NuCana (NCNA) Change in Intangibles (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Change in Intangibles data on file, last reported at -$66508.3 in Q4 2025.
- For the quarter ending Q4 2025, Change in Intangibles fell 3.64% year-over-year to -$66508.3; the trailing twelve-month figure through Dec 2025 stood at -$275959.3 (up 25.15% YoY), and the FY2025 full-year result was -$254472.5, up 31.12% from the prior year.
- Change in Intangibles eased to -$66508.3 in Q4 2025, from -$63420.0 in the prior quarter.
- In the past five years, Change in Intangibles ranged from a high of -$63420.0 in Q3 2025 to a low of -$625476.9 in Q4 2021.
- A 5-year average of -$176059.4 and a median of -$129458.1 in 2022 frame the typical range for Change in Intangibles.
- Peak annual rise in Change in Intangibles reached 62.7% in 2021, while the deepest fall reached 146.71% in 2021.
- Tracing NCNA's Change in Intangibles over 5 years: stood at -$625476.9 in 2021, then jumped by 77.85% to -$138524.6 in 2022, then rose by 13.09% to -$120391.7 in 2023, then jumped by 46.69% to -$64175.1 in 2024, then retreated by 3.64% to -$66508.3 in 2025.
- Business Quant data shows NCNA's Change in Intangibles at -$66508.3 in Q4 2025, -$63420.0 in Q3 2025, and -$64175.1 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | - |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | - |
| 10 | NuCana | 14.94 Bn | 14.91 Bn | - | -66,508.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -66,508.31 |
| Dec 31, 2025 | -66,508.31 |
| Sep 30, 2025 | -63,420.02 |
| Sep 30, 2025 | -63,420.02 |
| Dec 31, 2024 | -64,175.09 |
| Dec 31, 2024 | -64,175.09 |
| Sep 30, 2024 | -81,855.91 |
| Sep 30, 2024 | -81,855.91 |
| Jun 30, 2024 | -119,910.97 |
| Jun 30, 2024 | -119,910.97 |
| Mar 31, 2024 | -102,749.97 |
| Mar 31, 2024 | -102,749.97 |
| Dec 31, 2023 | -120,391.73 |
| Dec 31, 2023 | -120,391.73 |
| Sep 30, 2023 | -108,934.89 |
| Sep 30, 2023 | -108,934.89 |
| Jun 30, 2023 | -165,179.94 |
| Jun 30, 2023 | -165,179.94 |
| Mar 31, 2023 | -193,266.01 |
| Mar 31, 2023 | -193,266.01 |